Abstract | BACKGROUND/AIM: No standard treatment has been established for poorly-differentiated neuroendocrine carcinomas (PDNEC). The aim of this study is to evaluate the response to the combination of three drugs. MATERIAL AND METHODS: RESULTS: Primary tumor site was: pancreas 7 (33%), lung 5 (24%), colon-rectum 5 (24%), unknown 3 (14%) and stomach 1 (5%). The response rate was 24% (0 complete response, 24% partial responses, 38% stable disease, 9% progression and 19% unassessable). The global overall survival (OS) is 13 months (range=1-29) and progression-free survival (PFS) was 6 months (range=1-11). CONCLUSION:
|
Authors | Emilio Bajetta, Laura Catena, Pamela Biondani, Sara Pusceddu, Monica Valente, Nadia Bianco, Eugenio Novelli |
Journal | Anticancer research
(Anticancer Res)
Vol. 34
Issue 10
Pg. 5657-60
(Oct 2014)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 25275070
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Neuroendocrine
(drug therapy, mortality, pathology)
- Cisplatin
(administration & dosage)
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Grading
- Retrospective Studies
- Treatment Outcome
|